For Immediate Release
For Further Information Contact
Therese Fergo 301-608-9292
Email Therese@unither.com

UNITED THERAPEUTICS ANNOUNCES FURTHER DETAILS CONCERNING FDA ADVISORY COMMITTEE REVIEW OF REMODULIN FOR PULMONARY ARTERIAL HYPERTENSION

CONFERENCE CALL SCHEDULED FOR AUGUST 9, 2001, 5:00 P.M. EDT

Research Triangle Park, NC and Silver Spring, MD, July 29, 2001. United Therapeutics Corporation (NASDAQ: UTHR) announced today that the Cardiovascular and Renal Drugs Advisory Committee review of Remodulin for Pulmonary Arterial Hypertension (PAH) would occur August 9, 2001, at 8:30 a.m. EDT at the National Institutes of Health, Jack Masur Auditorium, Building 10, 9000 Rockville Pike, Bethesda, Maryland.

The company's President, Dr. Roger Jeffs, and its CEO, Martine Rothblatt, will host a conference call after the Advisory Committee meeting at 5:00 p.m. EDT to discuss the results. To participate in this call, dial 1-800-450-0819. A replay of the conference call will be available from 8:30 p.m. on August 9th until 8:30 p.m. on August 11th by dialing 1-800-475-6701 and using the access code 597788.

The company also announced that the principal presenters at the Advisory Committee meeting of Remodulin's safety, efficacy and risk/benefit analysis will be Stuart Rich, MD, and Robyn Barst, MD, heads of the two largest pulmonary hypertension clinical practices in the United States.

United Therapeutics submitted its New Drug Application (NDA) for Remodulin for PAH to the FDA on October 16, 2000. Pursuant to the Prescription Drug User Fee Act (PDUFA), FDA action on the NDA was required not later than July 16, 2001. Because the August 9, 2001, Advisory Committee meeting fell outside the PDUFA time period, the company was required to withdraw its NDA and will resubmit it upon a favorable Advisory Committee recommendation by the following day, August 10, 2001. The actual NDA has not moved between the FDA and the company. The resubmission will reference the Advisory Committee deliberations.

The company also submitted a regulatory approval application in France in January 2001, as the lead country for European approvals. Action on that application is expected before the end of 2001.

Over 500 PAH patients in North America, Europe and Australia continue to use Remodulin in open label studies sponsored by the company. This represents about 25% of the patients using the only currently approved drug for PAH, a continuous intravenous formulation of prostacyclin known as Flolan.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious diseases with unique therapeutic products. United Therapeutics is a member of the Russell 3000 Index and is included in the iShares Nasdaq Biotechnology Index Fund (NBI).

This press release contains forward-looking statements. These statements are subject to risks and uncertainties, which may cause actual results to differ materially from those indicated by the forward-looking statements, including those related to regulatory approval in the United States and Europe.